Skip to main content

Advertisement

SpringerLink
Log in

The Gene Mutation Spectrum of Breast Cancer Analyzed by Semiconductor Sequencing Platform

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

To use the semiconductor sequencing platform (SSP) to analyze the gene mutate spectrum of breast cancer patients. We recruited 46 breast cancer patients, and detected the ER/PR/HER2 expression level of the tumor tissue by immunohistochemistry. In addition, combined with SSP technology, we detected 207 hot mutation regions of 50 breast cancer related genes with multiple polymerase chain reaction (PCR) technology. There were 8 cases of grade I, 18 cases of grade II, 20 cases of grade III in 46 breast cancer patients according to histological grade and 12 cases of ER/PR + HER2 +, 18 cases of ER/PR + HER2−, 13 cases of ER/PR - HER2 +, 20 cases of ER/PR − HER2− according to ER/PR/HER2 status classification. Moreover, we found that there were 33 gene locus mutations of 8 genes including AKT1, APC, BRAF, CDKN2A, KRAS, PTEN, PIK3CA and TP53, but difference was not statistically significant (P > 0.05) when compared these gene mutations (except for PIK3CA) in each groups according to the histological classification of breast cancer and the ER/PR/HER2 classification. PIK3CA mutation rate of grade I was obviously higher than that of grade II ~ III histological grading in breast cancer patients (P < 0.05). Based on our results, we drew a conclusion that the occurrence and development of breast cancer was a process involved multiple genes. Here, we found that PIK3CA played a role in the development of the early stage of breast cancer, which could provide clinical basis for treatment of breast cancer. Moreover, SSP technology could be an effective and sensitive method for detection of gene mutation spectrum in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70

    Article  Google Scholar 

  2. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE (2014) Breast cancer in China. Lancet Oncol 15: e279–289

  3. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers 2014:513158

    Article  Google Scholar 

  4. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009

    Article  Google Scholar 

  5. Kittaneh M, Montero AJ, Gluck S (2013) Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer 5:61–70

    Article  Google Scholar 

  6. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F (2015) Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol 144:713–721

    Article  CAS  Google Scholar 

  7. Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkanen L, Turpeenniemi-Hujanen T, Joensuu H (2001) Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 19:28–36

    Article  CAS  Google Scholar 

  8. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536

    Article  Google Scholar 

  9. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292–10301

    Article  CAS  Google Scholar 

  10. Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF (2015) Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res 17:134

    Article  Google Scholar 

  11. Almendro V, Fuster G (2011) Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol 13:767–773

    Article  CAS  Google Scholar 

  12. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P (2005) Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 11:278–280

    Article  CAS  Google Scholar 

  13. Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK (2017) Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: a cohort study. Cancer 123:1115–1123

    Article  CAS  Google Scholar 

  14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826

    Article  CAS  Google Scholar 

  15. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657

    Article  CAS  Google Scholar 

  16. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402

    Article  CAS  Google Scholar 

  17. Bhat-Nakshatri P, Goswami CP, Badve S, Magnani L, Lupien M, Nakshatri H (2016) Molecular insights of pathways resulting from two common PIK3CA mutations in breast Cancer. Cancer Res 76:3989–4001

    Article  CAS  Google Scholar 

  18. Mayer IA, Arteaga CL (2014) PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer? J Clin Oncol 32:2932–2934

    Article  CAS  Google Scholar 

  19. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kummel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747–756

    Article  Google Scholar 

  20. Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, Leystra AA, Pasch CA, Jeffrey JJ, Clipson L, Matkowskyj KA, Deming DA (2015) PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis 4:e169

    Article  CAS  Google Scholar 

  21. Liang X, Lau QC, Salto-Tellez M, Putti TC, Loh M, Sukumar S (2006) Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther 5:544–548

    Article  CAS  Google Scholar 

  22. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L (2008) PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 10:R27

    Article  Google Scholar 

  23. Huszno J, Grzybowska E (2018) TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer. Oncol Lett 16:34–40

    PubMed  PubMed Central  Google Scholar 

  24. Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L, da Silva Filho AL, Friedman E (2016) The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases. In: Belo Horizonte, Brazil, Cancer Genet, 209, pp 50–52

    Google Scholar 

  25. Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH (2012) Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 14:R66

    Article  CAS  Google Scholar 

  26. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988–1004

    Article  CAS  Google Scholar 

  27. Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3:1221–1224

    Article  CAS  Google Scholar 

  28. M. Lapierre, S. Bonnet, C. Bascoul-Mollevi, I. Ait-Arsa, S. Jalaguier, M. Del Rio, M. Plateroti, P. Roepman, M. Ychou, J. Pannequin, F. Hollande, M. Parker, V. Cavailles, RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis, J Clin Invest, 124 (2014) 1899–1913

  29. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149:1192–1205

    Article  CAS  Google Scholar 

  30. Sanchez-Munoz A, Gallego E, de Luque V, Perez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E (2010) Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10:136

    Article  Google Scholar 

  31. Premalatha BR, Patil S, Rao RS, Reddy NP, Indu M (2013) Odontogenic tumor markers - an overview. J Int Oral Health 5:59–69

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Nagore E, Montoro A, Garcia-Casado Z, Botella-Estrada R, Insa A, Lluch A, Lopez-Guerrero JA, Guillen C (2009) Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer. Melanoma Res 19:211–214

    Article  CAS  Google Scholar 

  33. Debniak T, Cybulski C, Gorski B, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Kowalska E, Oszurek O, Narod SA, Lubinski J (2007) CDKN2A-positive breast cancers in young women from Poland. Breast Cancer Res Treat 103:355–359

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank financial support of Dongguan City Social Science and Technology Development Project (Grants No.2015108101030).

Funding

Dongguan Social development projiet (2015108101030).

Author information

Authors and Affiliations

  1. Dongguan Institute of Reproductive and Genetic Research, Dongguan Maternal and Child Health Hospital, Dongguan, 523000, Guangdong, China

    Yanhui Liu, Bo Yang & Xiaoyan Zhang

  2. CapitalBio Technology Inc., Beijing, 101111, China

    Quanfei Huang & Hailiang Liu

Authors
  1. Yanhui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoyan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Quanfei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hailiang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yanhui Liu or Hailiang Liu.

Ethics declarations

Conflict of Interest

The authors declare no conflict of interest.

Ethics Approval

This study was approved by the Ethics Committee of Dongguan Maternal and Child Health Care Hospital.

Additional information

Yanghui Liu and Bo Yang as co-first authors.

Yanhui Liu and Hailiang Liu authors contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Yang, B., Zhang, X. et al. The Gene Mutation Spectrum of Breast Cancer Analyzed by Semiconductor Sequencing Platform. Pathol. Oncol. Res. 26, 491–497 (2020). https://doi.org/10.1007/s12253-018-0522-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-018-0522-5

Keywords

Search

Navigation